Studies showed that in NSCLC without EGFR-TKI, the incidence of T790 mutation was less than 0.1%, while 50% of patients receiving EGFR-TKI acquired resistance resulting from T790 mutations.[18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.